2-[1-[1-[5-[3-Methyl-4-(1-phenylethoxycarbonylamino)-1,2-oxazol-5-yl]pyridin-2-yl]piperidin-4-yl]cyclopropyl]acetic acid

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-[1-[1-[5-[3-Methyl-4-(1-phenylethoxycarbonylamino)-1,2-oxazol-5-yl]pyridin-2-yl]piperidin-4-yl]cyclopropyl]acetic acid
• 英文别名: 2-[1-[1-[5-[3-methyl-4-(1-phenylethoxycarbonylamino)-1,2-oxazol-5-yl]pyridin-2-yl]piperidin-4-yl]cyclopropyl]acetic acid
• 化学式: C₂₈H₃₂N₄O₅
• 分子量: 504.6
• InChiKey: NJEIDQNVQBEEOY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.5
• 重原子数：
  37
• 可旋转键数：
  9
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  118
• 氢给体数：
  2
• 氢受体数：
  8

文献信息

• HETEROCYCLIC COMPOUNDS USEFUL IN THE TREATMENT OF DISEASE
  申请人：EPIGEN BIOSCIENCES, INC.

  公开号：US20160024031A1

  公开（公告）日：2016-01-28

  Heterocyclic compounds are described that are lysophosphatidic acid receptor ligands that are useful in the treatment of lysophosphatidic acid receptor-dependent diseases and conditions, including but not limited to diseases involving fibrosis, such as fibrosis of the heart, kidney, liver and lung, and scleroderma; inflammatory diseases such as diabetic nephropathy and inflammatory bowel disease; ocular diseases such as diseases involving retinal degeneration; nerve diseases such as pruritus and pain. Non-limiting examples of those compounds include (RS)-3-Cyclopropyl-2-4-[3-methyl-4((R)-1-phenyl-ethoxycarbonylamino)-isoxazol-5-yl]-benzyloxy}-propionic acid and (R)-1-(4′-5-[1-(2-Chloro-phenyl)-ethoxycarbonylamino]-4-fluoro-pyrazol-1-yl}-2-fluoro-biphenyl-4-yl)-cyclopropanecarboxylic acid.

  描述了异环化合物，这些化合物是溶血磷脂酸受体配体，可用于治疗溶血磷脂酸受体依赖性疾病和状况，包括但不限于涉及纤维化的疾病，如心脏、肾脏、肝脏和肺的纤维化以及硬化病；炎症性疾病，如糖尿病肾病和炎症性肠病；眼病，如涉及视网膜变性的疾病；神经疾病，如瘙痒和疼痛。这些化合物的非限制性例子包括(RS)-3-环丙基-2-4-[3-甲基-4((R)-1-苯基-乙氧羰基氨基)-异恶唑-5-基]-苄氧基}-丙酸和(R)-1-(4′-5-[1-(2-氯-苯基)-乙氧羰基氨基]-4-氟-吡唑-1-基}-2-氟-联苯-4-基)-环丙烷甲酸。
• Heterocyclic compounds useful in the treatment of disease
  申请人：EPIGEN BIOSCIENCES, INC.

  公开号：US10000459B2

  公开（公告）日：2018-06-19

  Heterocyclic compounds are described that are lysophosphatidic acid receptor ligands that are useful in the treatment of lysophosphatidic acid receptor-dependent diseases and conditions, including but not limited to diseases involving fibrosis, such as fibrosis of the heart, kidney, liver and lung, and scleroderma; inflammatory diseases such as diabetic nephropathy and inflammatory bowel disease; ocular diseases such as diseases involving retinal degeneration; nerve diseases such as pruritus and pain. Non-limiting examples of those compounds include (RS)-3-Cyclopropyl-2-4-[3-methyl-4-((R)-1-phenyl-ethoxycarbonylamino)-isoxazol-5-yl]-benzyloxy}-propionic acid and (R)-1-(4′-5-[1-(2-Chloro-phenyl)-ethoxycarbonylamino]-4-fluoro-pyrazol-1-yl}-2-fluoro-biphenyl-4-yl)-cyclopropanecarboxylic acid.

  所述杂环化合物是溶血磷脂酸受体配体，可用于治疗溶血磷脂酸受体依赖性疾病和病症，包括但不限于涉及纤维化的疾病，如心脏、肾脏、肝脏和肺部纤维化以及硬皮病；炎症性疾病，如糖尿病肾病和炎症性肠病；眼部疾病，如涉及视网膜变性的疾病；神经疾病，如瘙痒和疼痛。这些化合物的非限制性实例包括 (RS)-3-Cyclopropyl-2-4-[3-methyl-4-((R)-1-phenyl-ethoxycarbonylamino)-isoxazol-5-yl]-benzyloxy}- 丙酸和 (R)-3-Cyclopropyl-2-4-[3-methyl-4-((R)-1-phenyl-ethoxycarbonylamino)-isoxazol-5-yl]-benzyloxy}- 丙酸。丙酸和(R)-1-(4′-5-[1-(2-氯苯基)-乙氧羰基氨基]-4-氟吡唑-1-基}-2-氟联苯-4-基)-环丙烷羧酸。
• Heterocyclic Compounds Useful In The Treatment of Disease
  申请人：EPIGEN BIOSCIENCES, INC.

  公开号：US20180297962A1

  公开（公告）日：2018-10-18

  Heterocyclic compounds are described that are lysophosphatidic acid receptor ligands that are useful in the treatment of lysophosphatidic acid receptor-dependent diseases and conditions, including but not limited to diseases involving fibrosis, such as fibrosis of the heart, kidney, liver and lung, and scleroderma; inflammatory diseases such as diabetic nephropathy and nonalcoholic steatohepatitis (NASH); ocular diseases such as diseases involving retinal degeneration; nerve diseases such as pruritus and pain.
• Heterocyclic Compounds Useful In The Treatment Of Disease
  申请人：EPIGEN BIOSCIENCES, INC.

  公开号：US20190135767A1

  公开（公告）日：2019-05-09

  A method for treating a lysophosphatidic acid-dependent disease or condition in a subject in need thereof is provided. The method includes administering to the subject a therapeutically effective amount of a heterocyclic compound. The heterocyclic compound is a lysophosphatidic acid receptor ligand. Lysophosphatidic acid-dependent diseases and conditions include diseases involving fibrosis, such as fibrosis of the heart, kidney, liver and lung, and scleroderma; inflammatory diseases such as diabetic nephropathy and inflammatory bowel disease; ocular diseases such as diseases involving retinal degeneration; nerve diseases such as pruritus and pain.